Navigation Links
Major discovery opens door to leishmania treatment
Date:10/6/2009

This release is available in French.

Leishmania is a deadly parasitic disease that affects over 12 million people worldwide, with more than 2 million new cases reported every year. Until recently, scientists were unsure exactly how the parasite survives inside human cells. That mystery has now been solved according to a new study published in Science Signaling by a team led by Dr. Martin Olivier a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University. It is hoped the new study will lead to the development of the first prophylactic treatment for leishmania.

Leishmania is typically a sub-tropical and tropical infectious disease transmitted through the bite of female phlebotomine sandflies. The parasites enter the bloodstream and are ingested by macrophage white blood cells where they block immune function and multiply, spreading to other tissues in the body. Leishmania can occur in cutaneous forms, which are generally curable, as well as in a more dangerous and potentially fatal visceral form.

The researchers discovered that a metalloprotease a molecule called GP63 found on the surface of the parasite, plays a role in neutralizing the macrophage's defences. "Our results demonstrate the mechanism through which the GP63 protease alters the function of the macrophages by activating its own negative regulatory mechanisms," says Dr. Olivier. "The infected cells act 'frozen', which hinders the body's innate inflammatory immune response and leads to infection."

The work is significant in that it is the first study that explains how the leishmania parasite blocks the immune function of macrophages. "Our research indicates that the GP63 protease is the target of choice for innovative future treatments, in terms of prevention," says Dr. Olivier.

The GP63 protease directly activates other key molecules that negatively regulate the function of the host cell. "Better control over the activation of these host molecules could be one promising approach to treating leishmania as well as other infectious diseases that use similar infection strategies," he added.


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. How mitochondrial gene defects impair respiration, other major life functions
2. BioConference Live Attracts Major Life Science Sponsors
3. Restoring a natural root signal helps to fight a major corn pest
4. Family planning a major environmental impact
5. Avoiding hysterectomy: Major interventional radiology E-collection info available
6. Researchers achieve major breakthrough with water desalination system
7. Major breakthrough in early detection and prevention of AMD
8. Researcher garners major award from NIH for further exploration into the mechanisms of obesity
9. Major funding to help cut CO2 emissions
10. Cells split personality is a major discovery into neurological diseases
11. Major international study challenges notions of how genes are controlled in mammals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
Breaking Biology Technology: